

Stratech

stratech.co.uk/signalchem info@stratech.co.uk

2019-nCoV Spike protein RBD (Y453F) Catalog No: C19SD-G234H

SARS-CoV-2 spike variant with Y453F mutation has been associated with independent outbreaks linked to mink farms in the Netherlands and Denmark. Structure modeling studies have indicated relatively weaker binding of spike glycoprotein Y453F mutant to human ACE2 Spike protein and ability to escape four of the six tested monoclonal antibodies compared to wild type SARS-COV-2. Hence, as the new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, RBD (Y453F) (319-541) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points



Fully functional Protein

$\bullet \circ \bullet \bullet$
$\mathbf{O} \bullet \bullet \mathbf{O}$

Activity determined by functional ELISA



QC/QA tested



Effective for COVID19 research

Competitors









Researchers analyzing Y453F Neutralization **Target Customers**



Biopharma developing Y453F targeting therapies







Government research Diagnostic kits R&D organizations

Scientists testing COVID19 inhibitors